Biotechnology News and Research

RSS

China-Biotics fourth-quarter revenues up 64.4% to $25.5 million

China-Biotics, Inc., a leading developer, manufacturer and distributor of probiotics products in China, today reported its financial results for the fourth quarter and the fiscal year ended March 31, 2010.

11 Jun 2010

Reprogrammed killer cells prevent metastasis

A team of researchers has developed a method to produce cells that kill tumour cells in the lab and prevent tumours forming in mouse models of cancer. Although the current work is in cells and mouse, if the research transfers to human biology, the new type of cell could be a new source for cell-based anticancer therapies.

11 Jun 2010

Patheon, Merck expand contract manufacturing agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed an expanded contract manufacturing agreement with Merck & Co., Inc. (known as MSD outside of the U.S.A. and Canada).

11 Jun 2010

Medidata extends Rave EDC platform with Targeted SDV

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today introduced Rave Targeted SDV, the newest extension to its Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution. Rave Targeted SDV provides clinical research sponsors and contract research organizations (CROs) with an auditable and scalable partial source document verification (SDV) solution that supports risk-based site monitoring strategies.

11 Jun 2010

Shenzhen Beike Biotechnology forms joint venture with SiriCell Technologies

Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.

11 Jun 2010

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Synthetech fourth-quarter revenue down 37%

Synthetech, Inc. today announced financial results for its fiscal fourth quarter and fiscal year, which ended March 31, 2010.

10 Jun 2010

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

10 Jun 2010

Formedix's design tools integrated with Nextrials' EDC and clinical trial data management platform

Nextrials, Inc., a leader in clinical research software and services, today announced that its electronic data capture (EDC) and clinical trial data management platform, Prism™, is now integrated with the study design tools offered by Formedix. Formedix's industry leading Origin™ products include database design tools based on the data standards developed by the Clinical Data Interchange Standards Consortium (CDISC), a platform that Nextrials fully supports.

10 Jun 2010

PAREXEL experts to present on biopharmaceutical industry issues at 46th DIA

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that several of its experts will present on important industry issues at the Drug Information Association (DIA) 46th Annual Meeting, being held from June 13 – 17, 2010 in Washington, DC.

From Parexel 10 Jun 2010

LAB Research completes development of novel drug investigation model

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that it has recently completed development of a novel drug investigation model focused on biodistribution and pharmacokinetic of biologics.

10 Jun 2010

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

ICON launches ICOLabs Medical Review Application

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of the ICOLabs Medical Review Application an innovative web based laboratory application that enables more efficient use of medical monitoring time.

10 Jun 2010

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Genzyme Corporation and Carl C. Icahn and certain of his affiliated private investment funds announced today an agreement to settle their proxy contest.

10 Jun 2010

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

Officials at Texas Tech University System's Office of Technology Commercialization announced Wednesday (June 9) the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.

10 Jun 2010

Dyadic signs non-binding term sheet with EnGen Bio for potential outlicense of C1 platform technology

Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

Argus Optical Mapping System for microbial whole genome analysis launched at ASM 2010 General Meeting

OpGen, Inc., a microbial genomics solutions company, announced the launch of the Argus Optical Mapping System for microbial whole genome analysis at the ASM 2010 General Meeting held in San Diego, CA May 23-27, 2010. The Argus Optical Mapping System is based on Optical Mapping Technology which generates ordered, whole genome restriction maps from single DNA molecules.

10 Jun 2010

Synteract joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Synteract has joined Medidata's ASPire to Win® channel partner program. A full-service contract research organization (CRO) with an increasing global presence and extensive experience working with emerging biotech, pharmaceutical and medical device sponsors, Synteract will offer services around Medidata Rave®, the market-leading electronic data capture (EDC) and clinical data management (CDM) solution.

9 Jun 2010